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Introduction
Leber congenital amaurosis (LCA) is the most severe 
form of inherited retinal dystrophy, with an onset of dis-
ease symptoms in the first years of life1 and an estimated 
prevalence of ~1 in 50,000 worldwide.2,3 Genetically, LCA 
is a heterogeneous disease, with 15 genes identified to 
date in which mutations are causative for LCA.4,5 The 
most frequently mutated LCA gene is CEP290, account-
ing for ~15% of all cases.3,4,6,7 Severe mutations in CEP290 
have been reported to cause a spectrum of systemic dis-
eases that, besides retinal dystrophy, are characterized by 
brain defects, kidney malformations, polydactyly, and/or 
obesity.8–11 There is no clear-cut genotype–phenotype cor-
relation between the combination of CEP290 mutations and 
the associated phenotypes, but individuals with LCA and 
early onset retinal dystrophy very often carry hypomorphic 
alleles.3,6,7,12,13 The by far most frequently occurring hypo-
morphic CEP290 mutation, especially in European countries 
and in the United States, is a change in intron 26 of CEP290 
(c.2991+1655A>G).3,6,7,12 This mutation creates a cryptic 
splice donor site in intron 26 which results in the inclusion of 
an aberrant exon of 128 bp in the mutant CEP290 mRNA, 
and inserts a premature stop codon (p.C998X). Alternative 
splicing of the cryptic exon into the mRNA occurs in some, 
but not all, mRNA transcripts, explaining the hypomorphic 
nature of this mutation.6
LCA, and other retinal dystrophies, for long have been 
considered incurable diseases. However, the first phase I/II 
clinical trials using gene augmentation therapy have led to 
promising results in a selected group of adult individuals with 
LCA or early onset RP with mutations in the RPE65 gene.14–17 
Unilateral subretinal injections of adeno-associated virus 
particles carrying constructs encoding the wild-type RPE65 
cDNA were shown to be safe and moderately effective in 
some individuals, without causing any adverse effects. In 
a follow-up study using younger subjects, visual improve-
ments were more sustained, especially in the children who 
all gained ambulatory vision.18 Together, these studies have 
shown the potential to treat LCA, and thereby enormously 
boosted the development of therapeutic strategies for other 
genetic subtypes of retinal dystrophies.19 However, due to the 
tremendous variety in gene size and technical limitations of 
the vehicles that are used to deliver therapeutic constructs, 
gene augmentation therapy may not be applicable to all 
genes.
An alternative therapeutic strategy depends on the use of 
antisense oligonucleotides (AONs) that are able to interfere 
with splicing, and include DNA or RNA molecules/analogues, 
that can be delivered either as naked oligonucleotides or 
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expressed by viral vectors. Although not applicable to all muta-
tions, AONs are ideally suited to block aberrant splice events 
caused by the activation of cryptic splice sites, and hence 
restore normal splicing. Here, we describe the use of AONs 
to redirect normal splicing of CEP290 in patient-derived lym-
phoblast cells, and show a sequence-specific and dose-de-
pendent decrease in levels of aberrantly spliced CEP290 that 
is accompanied by an increase in correctly spliced CEP290 
mRNA, thereby revealing the potential of AON-based therapy 
to treat CEP290-associated LCA.
Results
The intronic CEP290 mutation (c.2991+1655A>G) cre-
ates a splice donor site that results in the inclusion of an 
aberrant exon into the CEP290 mRNA (Figure 1a and b). 
Addition of AONs directed against the aberrant exon would 
prevent the insertion of this exon by preventing the binding 
of factors that are essential for splicing such as the U1- and 
U2snRNP complexes, and serine-arginine rich proteins, 
thereby restoring normal CEP290 splicing and protein syn-
thesis (Figure 1c). AONs can target splice sites as well as 
exonic sequences, although in the particular case of the 
Duchenne muscular dystrophy (DMD) gene, AONs target-
ing exonic regions tend to outperform those that target the 
splice sites.20 In addition, previous studies have suggested a 
positive correlation between the capability of AONs to induce 
exon skipping and the presence of predicted SC35 splice 
factor binding sites in the target sequence.21 To design an 
AON with high exon-skipping potential, the aberrant CEP290 
exon (128 nucleotides exonic sequence plus 15 nucleotides 
of intronic sequence on each side) was scrutinized for exonic 
splice enhancer-binding motifs, using the ESE finder 3.0 
Figure 1 CEP290 splicing and antisense oligonucleotide (AON) function. (a) Normal CEP290 mRNA splicing of exons 26 and 27, 
resulting in wild-type CEP290 protein. (b) The most frequent Leber congenital amaurosis (LCA)-causing mutation is an A-to-G transition 
(underlined and indicated with an asterisk) in intron 26 of CEP290. This mutation creates a splice donor site, which results in the inclu-
sion of an aberrant exon to part of the CEP290 mRNA and subsequent premature termination of the CEP290 protein. (c) Upon binding of 
sequence-specific AONs, factors involved in splicing will not recognize the aberrant splice donor site in intron 26, resulting in redirection of 
normal CEP290 splicing and synthesis of a full-length CEP290 protein.
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program.22 At the 3′-end of the aberrant exon, two SC35-
binding motifs were predicted (data not shown). Hence, the 
first AON was designed such that it encompassed these two 
motifs (designated AON-3).
To determine whether AON-3 has exon-skipping potential 
in vitro, immortalized lymphoblastoid cells of two unrelated 
individuals with LCA homozygously carrying the intronic 
CEP290 founder mutation c.2991+1655A>G, as well as one 
control individual, were cultured in the absence or presence 
of 1 μmol/l AON-3. As expected, in the control individual, only 
a band representing correctly spliced CEP290 was observed, 
whereas in both affected individuals two products were pres-
ent, one representing correctly spliced, and one represent-
ing aberrantly spliced CEP290 mRNA. Upon addition of 
AON-3, a strong decrease in aberrantly spliced CEP290 was 
noted, in both individuals with LCA (Figure 2a). Next, the 
specificity of AON-3 was assessed by transfecting a sense 
oligonucleotide directed to the same target site (SON-3). 
Reverse transcription-PCR analysis showed that in the cells 
transfected with SON-3, both the aberrantly spliced and the 
correctly spliced CEP290 mRNA molecules are still pres-
ent (Figure 2b, left panel), demonstrating the specificity of 
the antisense sequence. Using an additional pair of primers 
that amplifies larger products, similar results were obtained 
 (Figure 2b, right panel). Interestingly, the decrease in aber-
rantly spliced CEP290 appears to coincide with an increased 
intensity of the product representing correctly spliced CEP290 
mRNA. These data indicate that the aberrant product is not 
degraded, but that the AON transfection truly induces exon 
skipping, resulting in the synthesis of more correctly spliced 
wild-type CEP290 mRNA. To determine the effective dose of 
AON-3, cells were transfected with various concentrations of 
AON-3, ranging from 0.01 to 1.0 μmol/l. Even at the lowest 
concentration of 0.01 μmol/l, a marked reduction in aber-
rantly spliced CEP290 was observed. The maximum amount 
of exon skipping was observed at 0.05 or 0.1 μmol/l of AON, 
indicating that these concentrations are sufficient to convert 
almost all aberrantly spliced CEP290 (Figure 2c).
Figure 2 Antisense oligonucleotide (AON)-based rescue of aberrant CEP290 splicing. (a) Reverse transcription-PCR (RT-PCR) 
analysis of CEP290 mRNA isolated from lymphoblastoid cells of one control individual and two individuals affected with Leber congenital 
amaurosis (LCA), that were cultured in the absence or presence of a selected AON (AON-3) directed against the aberrant CEP290 exon in 
a final concentration of 1.0 μmol/l. The upper band represents the aberrant CEP290 splice product, whereas the lower band represents the 
wild-type CEP290 splice product. M, 100-bp marker. MQ, negative water control. (b) Specificity of AON-based rescue. Similar to (a), cells 
were transfected with AON-3, or a sense oligonucleotide directed to the same target site (SON-3). Left panel: RT-PCR using primers  located 
in exon 26 and exon 27. Right panel: RT-PCR using primers located in exon 26 and exon 31. (c) Dose-dependent rescue of CEP290 mRNA 
splicing. Similar to (a), cells were transfected with different concentrations of the selected AON, ranging from 0.01 to 1.0 μmol/l.
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The effectiveness of AONs in splice modulation is thought 
to depend merely on the accessibility of the target mRNA 
molecule, and hence may differ tremendously between neigh-
boring sequences. To determine whether this sequence spec-
ificity also applies for CEP290, several AONs were designed 
that target the aberrant CEP290 exon (Table 1). This exon 
consists of 128 base pairs, the majority of which are part of an 
Alu repeat, one of the most frequent repetitive elements in the 
human genome,23 covering the entire 5′-end of the aberrant 
exon (Figure 3a). Hence, the majority of AONs were designed 
to be complementary to the 3′-end of the aberrant exon or the 
splice donor site (Figure 3a). In total, five AONs were trans-
fected at a final concentration of 0.1 μmol/l, which was shown 
to be optimal for AON-3. Besides AON-3, also AON-2 and 
AON-4 resulted in high levels of exon skipping. In contrast, 
AON-1 that targets the Alu repeat region, and AON-5 that 
is directed against the splice donor site, hardly showed any 
exon-skipping potential (Figure 3b). This sequence-specific 
effect is likely caused by secondary structures of the target 
mRNA that prevent the binding of AONs. Together, our data 
demonstrate the sequence specificity in AON-based exon 
skipping of CEP290 and highlight a small region of the aber-
rant CEP290 exon as a potential therapeutic target.
Discussion
In this study, we explored the therapeutic potential of AONs 
to correct a splice defect caused by an intronic mutation in 
CEP290. In immortalized lymphoblast cells of individuals 
with LCA homozygously carrying the intronic CEP290 muta-
tion c.2991+1655A>G, transfection of some but not all AONs 
resulted in skipping of the aberrant exon, thereby almost fully 
restoring normal CEP290 splicing.
AONs have been the focus of therapeutic research for over 
a decade, for the treatment of a variety of genetic  diseases.24 
These strategies include the use of AONs to block the rec-
ognition of aberrant splice sites, to alter the ratio between 
two naturally occurring splice isoforms, to induce skipping of 
exons that contain protein-truncating mutations, or to induce 
the skipping of exons in order to restore the reading-frame 
of a transcript that is disrupted by a genomic deletion, which 
allows the synthesis of a (partially) functional protein.24 The 
latter approach is already being applied in phase I/II clinical 
trials for the treatment of individuals affected with Duchenne 
muscular dystrophy, with promising results.25,26
The intronic CEP290 mutation is an ideal target for AON-
based therapy, since this mutation results in the inclusion of 
an aberrant exon in the CEP290 mRNA which is normally 
not transcribed. Inducing skipping of this aberrant exon by 
Table 1 Antisense oligonucleotide sequences
RNA  
oligonucleotide
Sequence (5′➔3′) T
m
 (ºC) Target in aberrant 
CEP290 exon (nt)
AON-1 taatcccagcactttaggag 58 72–91
AON-2 gggccaggtgcggtgg 58 102–117
AON-3 aactggggccaggtgcg 58 106–122
AON-4 tacaactggggccaggtg 58 108–125
AON-5 actcacaattacaactgggg 58 115–128+6
SON-3 cgcacctggccccagtt 58 Nontargeting
Abbreviation: AON, antisense oligonucleotide.
Overview of the sequences of the AONs used in this study. The right column 
depicts the position of the target sequence in the aberrant CEP290 exon. 
AON-5 is directed against the 14 most 3′-exonic nucleotides and the first six 
nucleotides of the splice donor site. SON-3 is complementary to AON-3 and 
thus does not target the aberrant CEP290 exon.
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Figure 3 Sequence specificity in antisense oligonucleotide (AON)-based rescue of aberrant CEP290 splicing. (a)  Overview of 
the aberrant CEP290 exon, and the relative positions of the AONs that were selected. The 5′-end of the aberrant exon is part of an Alu 
repeat. (b) Reverse transcription-PCR (RT-PCR) analysis of CEP290 mRNA isolated from lymphoblastoid cells of an individual with Leber 
congenital amaurosis (LCA) that were cultured in the absence or presence of different AONs directed against the aberrant CEP290 exon 
(AON-1 to AON-5), or one sense oligonucleotide (SON-3). The AONs and SON were transfected in a final concentration of 0.1 μmol/l. The 
upper band represents the aberrant CEP290 splice product, whereas the lower band represents the wild-type CEP290 splice product. M, 
100-bp marker. MQ, negative water control.
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AONs appears to almost fully restore the normal CEP290 
mRNA, allowing normal levels of CEP290 protein to be syn-
thesized. A similar approach has been successful in individ-
uals with Duchenne or Becker muscular dystrophy carrying 
intronic mutations in DMD, where addition of AONs resulted 
in the generation of wild-type dystrophin protein.27 A second 
major advantage is that although this AON-approach is a 
mutation-specific therapeutic strategy, the intronic CEP290 
mutation is by far the most frequent LCA-causing mutation.4 
Based on the estimated prevalence of LCA (1:50,000), and 
the observed frequency of the intronic CEP290 mutation 
in Northern-Europe (26%)28 and the United States (10%),3 
at least one thousand and, depending on the frequency of 
the mutation in other populations, perhaps many more indi-
viduals worldwide have LCA due to this mutation. Finally, 
although the LCA phenotype associated with CEP290 muta-
tions is severe, it appears that the photoreceptor integrity, 
especially in the macula, as well as the anatomical struc-
ture of the visual connections to the brain, are relatively 
spared in individuals with LCA carrying CEP290 mutations, 
which would allow a window of opportunity for therapeutic 
intervention.29
The study described here provides a proof-of-principle of 
AON-based therapy for CEP290-associated LCA in vitro, 
using immortalized lymphoblast cells from affected individu-
als. In order to determine the true therapeutic potential of this 
method for treating LCA, additional studies are needed that 
include the development of therapeutic vectors, and assess-
ment of efficacy and safety in animal models. AONs can be 
delivered in two ways, either as naked molecules (or conju-
gated to cell-penetrating peptides), or via viral vectors. A sin-
gle injection of naked AONs has recently been shown to be 
effective for several months in a mouse model for spinal mus-
cular atrophy.30 Naked AONs can be delivered to the retina 
by intraocular injections, although in each individual multiple 
injections would still be required. Alternatively, by using viral 
vectors, a single subretinal injection would suffice to allow 
a long-term expression of the therapeutic construct. Previ-
ously, others have used recombinant adeno-associated viral 
(rAAV) vectors carrying U1- or modified U7snRNA constructs 
to efficiently deliver AON sequences, in the mdx mouse 
model for DMD, or in myoblasts from individuals with DMD, 
respectively.31,32 In line with this, AONs targeting the aber-
rant exon of CEP290 could be cloned into such constructs, 
and delivered to the retina by subretinal injections of rAAV-5 
or -8 serotypes that efficiently transduce photoreceptor cells 
where the endogenous CEP290 gene is expressed.33,34 
Using rAAV-2 vectors, no deleterious immune response was 
evoked upon subretinal injections of these vectors in individu-
als with RPE65 mutations,35 and also for rAAV-5 and rAAV-8, 
immune responses appear to be benign, at least in animal 
models.36,37 One final safety aspect concerns the specific-
ity of the sequence that is used to block the splicing of the 
aberrant CEP290 exon. As stated before, the majority of this 
exon is part of an Alu repeat, and AONs directed against this 
repeat will likely bind at multiple sites in the human genome, 
increasing the chance to induce off-target effects. The AONs 
that were shown to be effective in this study do not fully target 
the Alu repeat sequence, but are also not completely unique 
in the human genome. However, when blasting against the 
EST database, no exact hits are found, indicating that at the 
level of expressed genes, these sequences are unlikely to 
induce off-target effects and deregulate normal splicing of 
other genes. To further study the efficacy and safety of AON-
based therapy for CEP290-associated LCA in vivo, including 
the use of AON expression driven by viral vectors, we are 
currently generating a transgenic knock-in mouse model that 
carries part of the human CEP290 gene (exon 26 to exon 27, 
with and without the intronic mutation) which is exchanged 
with its mouse counterpart.
Compared to gene augmentation therapy, AON-based 
therapy has a number of advantages. First, in gene augmen-
tation therapy, a ubiquitous or tissue-specific promoter is 
used to drive expression of the wild-type cDNA encoding the 
protein that is mutated in a certain individual. For instance 
in one clinical trial for RPE65 gene therapy, the chicken 
beta-actin promoter was used.17 Using either constitutive 
promoters or fragments of the endogenous promoters, it is 
difficult to precisely control the levels of expression of the 
therapeutic gene. In some cases, like for the RPE65 protein 
that has an enzymatic function, expression levels beyond 
those of the endogenous gene might not be harmful to the 
retina. For other genes however, including those that encode 
structural proteins like CEP290, tightly-regulated expression 
levels might be crucial for cell survival, and overexpression 
of the therapeutic protein might exert toxic effects. Using 
AONs, the therapeutic intervention occurs at the pre-mRNA 
level, and hence does not interfere with the endogenous 
expression levels of the target gene. A second issue is the 
use of the viral vector. Of a variety of different recombinant 
viral vectors, rAAVs are considered to be most suitable for 
treating retinal dystrophies, because of their relatively high 
transduction efficiency of retinal cells, and their limited 
immunogenicity. The major drawback of rAAVs however is 
their limited cargo size of 4.8 kb. Again, for some genes like 
RPE65, this is not a problem. For many other retinal genes 
however, including CEP290 (with an open reading frame of 
7.4 kb), but also ABCA4 and USH2A, the size of their full-
length cDNAs exceeds the cargo size of the currently avail-
able pool of rAAVs. One way to overcome this problem is 
to express cDNAs that express only partial proteins with 
residual activity, as has been suggested for CEP290 in two 
studies employing the zebrafish model, either by expressing 
the N-terminal region of the protein38 or a 299-amino acid 
domain of CEP290 that is deleted in the rd16 mouse.39 Other 
viral vectors, like lentivirus or adenoviruses have a higher 
cargo capacity than rAAVs (~8 kb), but are less efficient in 
transducing retinal cells, and in addition, adenovirus has a 
higher immunogenic potential.19 For AON-based therapy, the 
size limitations of AAV are not a problem, since the small 
size of the AONs and the accompanying constructs easily fit 
within the available rAAVs.
In conclusion, this study shows that administration of 
AONs to cultured cells of affected individuals almost fully 
corrects a splice defect that is caused by a frequent intronic 
mutation in CEP290 that causes LCA. These data warrant 
further research to determine the therapeutic potential of 
AON-based therapy for CEP290-associated LCA, in order to 
delay or cease the progression of this devastating blinding 
disease.
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Materials and Methods
Design AONs. The 128-bp sequence of the aberrant CEP290 
exon that is included into the mutant CEP290 mRNA was 
analyzed for the presence of exonic splice enhancer motifs 
using the ESE finder 3.0 program (http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home). RNA AONs 
were purchased from Eurogentec, and designed with a T
m
 
of 58°C, and modified with a 2′-O-methyl group at the sugar 
chain and a phosphorothioate backbone, and dissolved in 
phosphate-buffered saline.
Cell culture. Human B-lymphoblast cells of individuals 
affected with LCA and homozygously carrying the intronic 
mutation in CEP290 were immortalized by transformation 
with the Eppstein–Barr virus, as described previously.40 Cells 
were cultured in RPMI1640 medium (Sigma, St Louis, MO) 
containing 10% (vol/vol) fetal calf serum (Sigma), 1% 10 U/μl 
penicillin and 10 μg/μl streptomycin (Sigma), at a density of 
0.5 × 106 cells/ml. Fresh medium was supplied twice a week.
Transfection of AONs. A day before transfection, 1.0 × 106 cells 
were seeded in each well of a 6-wells plate, in a total volume 
of 2 ml complete medium. Transfection mixtures were pre-
pared by combining 2.5 μl AON in a desired concentration, or 
distilled water, 5 μl transfection reagent (ExGen in vitro 500; 
Fermentas, St Leon-Rot, Germany) and 92.5 μl 150 mmol/l 
NaCl, and incubated at room temperature for 10 minutes, 
before addition to the cells. Six hours after transfection, 8 ml 
of low-serum medium (complete medium with only 1% fetal 
calf serum) was added. Forty-eight hours after transfection, 
cells were collected and washed with 1× phosphate-buffered 
saline, before directly proceeding to RNA isolation.
RNA isolation and reverse transcription-PCR. Total RNA 
was isolated from transfected lymphoblastoid cells using 
the Nucleospin RNA II isolation kit (Machery Nagel, Düren, 
Germany), according to manufacturer’s protocol. Subse-
quently, 1 μg of total RNA was used for cDNA synthesis 
using the iScript cDNA synthesis kit (Bio-Rad, Veenendaal, 
the Netherlands). Five percent of the cDNA was used 
for each PCR. Part of the CEP290 cDNA was ampli-
fied under standard PCR conditions supplemented with 
5% Q- solution (Qiagen, Hilden, Germany), and using for-
ward primer 5′-TGCTAAGTACAGGGACATCTTGC-3′ and 
reverse primer 5′-agactccacttgttcttttaaggag-3′ 
or 5′-tggcaatgagcgactttc-3′ that are located in exon 
26, exon 27, and exon 31 of the human CEP290 gene, 
respectively. PCR products were resolved on a 1.5% aga-
rose gel. Bands presumably representing correctly and aber-
rantly spliced CEP290 were excised from the gel, purified 
using Nucleospin Extract II isolation kit and sequenced from 
both strands with the ABI PRISM Big Dye Terminator Cycle 
Sequencing V2.0 Ready Reaction kit and the ABI PRISM 
3730 DNA analyzer (Applied Biosystems, Foster City, CA).
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